Darovasertib (LXS196) is a potent, selective PKC inhibitor. It affects PKC signaling, by blocking kinase activity, inhibiting uveal melanoma (UM) progression, and is safely evaluated in combination with crizotinib.
Darovasertib (LXS196) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for Darovasertib (LXS196) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.